What is the controversy with NAD+? Shocking Insights

Understanding the fuss: why NAD+ supplements are everywhere and why some experts worry

NAD+ supplements are a frequent headline in health magazines and clinic brochures. At their best they promise to boost cellular energy and support healthy aging; at times the messages feel hopeful and at others alarmist. This article is written to be clear, practical, and evidence-minded. We will explore the science behind NAD+, the different products on the market, what human clinical trials through 2024–2025 actually show, and the safety and regulatory questions you should consider before trying NAD+ supplements.

What is NAD+ and why does it matter?

NAD+ stands for nicotinamide adenine dinucleotide. It is a tiny but essential molecule inside every cell that participates in energy production, helps enzymes called sirtuins that influence cellular repair, and acts as a signaling switch for metabolism and stress responses. As people age, levels of NAD+ tend to fall in many tissues, which is why researchers hypothesize restoring NAD+ might help maintain cellular function. That biochemical plausibility is a strong reason researchers and product makers have focused on NAD+ supplements, but plausibility is not the same as proven long-term benefit.

How NAD+ supplements work: the basics

There are several pathways to raise intracellular NAD+. Traditional dietary forms include niacin (nicotinic acid) and nicotinamide. Newer molecules that are closer to NAD+ in the biochemical chain include nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). When taken orally, NR and NMN have been shown in multiple human clinical trials to increase blood levels of NAD-related metabolites. Those consistent biochemical effects are real and reproducible across studies. But changing a blood marker is only the first step. Translating that change into improvements in cognition, metabolism, mobility, or longevity requires longer and larger human trials.

Types of products you will encounter

Oral precursors: NR and NMN

NR and NMN are available as oral supplements. In randomized human clinical trials, oral NR and NMN most consistently show increases in circulating NAD+ metabolites. Side effects in short trials are usually mild and gastrointestinal. The simplicity of taking a pill is appealing; the liver and gut act as filters that moderate how quickly the body sees the compound.

Traditional vitamin forms: niacin and nicotinamide

Niacin reliably raises NAD-related chemistry but often causes flushing at higher doses. Nicotinamide is commonly used at nutritional doses and is safe in that range, but very high doses have different and less well-studied effects. These are inexpensive and well-known, but their clinical effects beyond preventing deficiency remain modest.

IV NAD infusions

Some clinics offer intravenous NAD, which promises rapid systemic exposure. IV NAD bypasses digestion and the first-pass liver effects and therefore can produce immediate physiologic changes. That potential benefit comes with different risks: immediate allergic reactions, hypotension, vein inflammation, and increased exposure to impurities or product-quality issues. Regulatory agencies and clinicians have questioned the safety and quality control of marketed IV NAD services because randomized controlled data to support routine IV use are limited.

What human clinical trials show so far

By 2024–2025 multiple randomized human clinical trials have tested NR and NMN. What they consistently show: oral dosing changes blood biomarkers related to NAD+ metabolism. Some trials report modest improvements in metabolic markers, insulin sensitivity, or mitochondrial signals in muscle. Others show no clear clinical benefit on cognitive tests, muscle strength, or glucose control when compared with placebo. Many trials are small, short, and designed to measure biochemical changes rather than long-term clinical outcomes. Large randomized trials measuring disease incidence, disability, or survival are largely absent.

Put another way: a pill reliably moves a number on a lab report; whether that translates into fewer heart attacks, better memory, or longer life is still an open question. Several recent reviews summarize the human-trial evidence and methodological challenges, including a review of NAD+-boosting compounds (https://pmc.ncbi.nlm.nih.gov/articles/PMC10692436/), an update on NMN biotherapy (https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05614-9), and a review linking NAD metabolism to metabolic liver disease (https://www.sciencedirect.com/science/article/pii/S258900422400395X).

Is increasing a biomarker enough?

Seeing a rise in an NAD metabolite can feel validating. But biology is a network, not a straight line. Increasing one metabolite may nudge one pathway forward and another sideways. A biomarker is necessary but rarely sufficient. Think of cholesterol: changing a single lipid does not capture cardiovascular health in full. Context, duration, and downstream effects matter.

Safety signals from trials and real-world reports

Randomized human clinical trials of oral NR and NMN typically report good short-term tolerability. Common adverse events are mild and include gastrointestinal discomfort. Laboratory abnormalities are uncommon in short trials. But trial participants are often healthier than real-world users and trials are often short.

Outside trials, reports from clinics and adverse-event databases include transient liver enzyme elevations, allergic reactions, and isolated serious events. These are relatively rare and causality is often uncertain, but they are reminders that real-world use can reveal risks not seen in small trials. Liver transaminase elevations are particularly notable because they can hint at hepatocellular stress. For many people the elevations resolve after stopping the product, but for those with pre-existing liver disease or those on interacting drugs the consequences could be more severe.

IV NAD concerns: product quality and acute risks

IV NAD infusions deserve special scrutiny. The intravenous route removes many of the body’s buffering mechanisms. Clinics vary in how they source, handle, and test IV NAD products. Acute reactions such as hypotension or allergic responses have been reported. Because the procedure is performed in elective settings, oversight and emergency preparedness may differ. If you consider IV NAD, ask about sourcing, testing, staff training, and medical oversight.

Drug interactions and sensitive populations

NAD+ metabolism intersects with many pharmacologic pathways. Drugs that influence liver enzymes or cellular metabolism could plausibly interact with NAD+ supplements. Cancer therapies are a particular concern because altering NAD biology could theoretically affect DNA repair and tumor metabolism. For that reason many oncologists advise against unmonitored NAD supplementation during active chemotherapy or targeted therapy.

Pregnant and breastfeeding people, children, and those with severe liver or kidney disease are groups with limited safety data and should generally avoid new systemic supplements unless supervised by a specialist.

Product quality: why the label may not tell the whole story

The supplement marketplace varies widely. Some manufacturers produce well-characterized NR or NMN with independent testing and clean supply chains. Others have inconsistent labeling, unlisted contaminants, or amounts that do not match the label. That variability complicates assessing both safety and efficacy. A vital practical step is to favor products with third-party testing and clear batch documentation.

Assay standardization is a separate problem

Laboratories measure different molecules—NAD+, NADH, and various NAD metabolites—using different methods. That makes it difficult to compare reports across trials. A reported twofold increase in one lab is not always equivalent to a twofold increase in another lab’s assay. Standardized assays would improve research clarity and consumer confidence.

Practical questions to ask before trying NAD+ supplements

Start with why. Are you taking an NAD+ supplement to change a lab marker, to recover from heavy training, to support metabolism, or to slow aging? The likely outcomes differ by goal. Next, check product quality and dose. Does the product show third-party testing? Does the dose align with what was used in human clinical trials or is it much higher? Finally, plan monitoring: baseline liver tests, medication review, and a repeat set of liver tests in a few weeks if you start a product.

Consider Tonum’s Motus (oral) as an example of an evidence-minded oral product from a company that publishes human trial data and emphasizes transparency; while Motus is not an NAD+ product it demonstrates the value of choosing companies that prioritize trials, third-party testing, and clear labeling.

How dosing and duration affect what we know

Clinical trials use a wide range of doses. Short-term studies measure biomarkers after weeks to months and are useful to establish target engagement. Long-term outcomes like disease prevention or longevity are not yet available. Taking higher-than-studied doses increases uncertainty and may raise risks. There is no universally agreed optimal dose for routine use.

Comparing oral supplements with IV NAD

Oral NR and NMN and IV NAD have different risk and benefit profiles. Oral products provide slower, buffered exposure with the gut and liver acting as physiologic filters. IV NAD produces fast systemic exposure and carries more immediate risks from product impurities, inconsistent dosing, and acute reactions. If you are weighing options, consider what outcomes you expect and what safety trade-offs you are willing to accept.

Regulatory and ethical questions

NAD+ products highlight familiar regulatory tensions. Dietary supplements often do not face the same premarket scrutiny as prescription drugs. Clinics offering IV NAD sometimes market services with claims that outpace evidence. Ethically, charging for a treatment that lacks controlled trial evidence raises questions about informed consent and appropriate patient expectations.

Real-world voices: brief case notes

One 58-year-old marathoner tried NR for several months, reported less perceived fatigue but no measurable race-time improvement, and had normal liver enzymes. A 45-year-old with fatty liver disease experienced mild transaminase elevations that resolved after stopping the supplement. Anecdotes are not scientific proof, but they remind us users vary and that monitoring is important.

Advice for clinicians

When patients ask about NAD+ supplements, ask about their goals, products, and medical history. Check for liver disease, cancer therapy, pregnancy, breastfeeding, or medications that affect liver enzymes. Recommend baseline liver tests and repeat testing if they start a product. Encourage patients to choose products with independent testing and transparent sourcing. If a patient pursues IV NAD, ask about the clinic’s medical oversight, product testing, and emergency preparedness.

Open research questions

Key unknowns remain: long-term safety of NR and NMN at commonly used doses, whether particular subgroups derive greater benefit, interactions with specific drugs, effects on cancer biology, and reliable assays for cross-study comparison. Answering these requires larger, longer randomized human clinical trials and better product standardization.

Simple checklist before you start

1. Define your goal for taking NAD+ supplements.
2. Discuss your plan with a clinician and list all medications.
3. Choose a product with third-party testing and clear labeling.
4. Get baseline liver tests and plan for follow-up labs.
5. Pause during pregnancy, breastfeeding, cancer therapy, or serious liver disease.

How to read marketing claims

Treat definitive marketing claims with skepticism. A product that promises to prevent aging or guarantee disease prevention is outpacing the available evidence. A responsible brand will clearly state what is known and what remains unknown and will point to human clinical trials rather than only lab or animal data.

Comparisons to other interventions

For context, prescription drugs like semaglutide (injectable) and tirzepatide (injectable) have robust human clinical trials for weight and metabolic benefits. They are very different interventions and routes of administration. When people ask whether a supplement can match those results they are often comparing apples and oranges. Oral, evidence-backed supplements like Motus (oral) from Tonum show meaningful human trial signals for metabolism and weight management but are not the same as prescription injectables and should be considered in that context.

Main Question for readers

People often wonder if they should try NAD+ supplements based on early science and marketing. The clearest short answer is: if you are curious and otherwise healthy, cautious experimentation with well-sourced oral NAD+ supplements and careful monitoring is reasonable; if you have liver disease, cancer, are pregnant, or take drugs that affect liver enzymes, defer and consult your clinician.

Practical scenarios and decision guides

If you train hard: an athlete might try an oral NAD+ supplement briefly to see if subjective recovery improves while monitoring liver tests. If you have metabolic syndrome: discuss with your clinician whether an NAD+ supplement is likely to add to established treatments like diet, exercise, and evidence-based medications. If you are facing cancer therapy: avoid NAD+ supplements unless explicitly cleared by your oncology team.

How to pick a trustworthy product

Look for transparent sourcing, third-party testing certificates, batch numbers, and a company willing to share trial data. Prefer manufacturers that use human clinical trials to support claims and that publish clear safety information. That transparency helps clinicians advise patients and helps users make informed choices.

Monitoring when you start

Baseline labs: ALT, AST, bilirubin, and a medication review. Repeat labs at 4–8 weeks and sooner if symptoms like abdominal pain, unusual fatigue, jaundice, or dark urine appear. Keep a symptom diary and record the exact product and batch you used; that helps clinicians diagnose adverse events if they occur.

What to do if you notice abnormal labs

If liver enzymes rise, stop the supplement and recheck labs in a few weeks. If enzymes remain elevated or symptoms appear, seek medical evaluation. Document the product, dose, and timing to support causality assessment. Many reported elevations have resolved on stopping the product, but rarer severe cases would need specialist care.

Takeaways for patients and clinicians

1. NAD+ supplements reliably change biochemical markers in humans but long-term clinical benefits are not yet proven. 2. Oral NR and NMN are generally well tolerated in short randomized trials, but real-world adverse events including liver enzyme elevations have been reported. 3. IV NAD carries different and potentially larger risks due to direct bloodstream exposure and variable product quality.

Final practical note

Science advances by careful trials, replication, and transparent reporting. NAD+ supplementation is an active area of research. If you try a product do so with modest expectations, informed consent, and appropriate monitoring. Brands that prioritize human clinical trials, third-party testing, and clear labeling make safer and more transparent partners for curious users.

Further reading and resources

For clinicians and researchers, ask for standardized assays and longer randomized human clinical trials. For consumers, prefer products with independent testing and clear trial references. If you want to explore Tonum’s research resources and publications, the company’s research hub is a place to start: Tonum research hub. A single glance at the Tonum brand logo can help you identify official resources.

Closing thought

NAD+ supplements are a plausible, actively studied approach to supporting cellular metabolism. They are not yet a proven, guaranteed therapy to prevent aging or chronic disease. Keep curiosity balanced by caution and clear monitoring.